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Molecular characterization of Staphylococcus aureus is of both clinical and infection control importance. Virulence determinants
using PCR and multiple drug resistance profiles were studied in 130 S. aureus isolates. PCR-RFLP analysis of the 16S–23S DNA
spacer region was done to investigate the level of 16S–23S ITS (internal transcribed spacer) polymorphism. Methicillin-resistant S.
aureus (MRSA), which represented 72% of the studied isolates, showed multiple drug resistance with 18% being resistant to 10–18
of the drugs used compared to a maximum resistance to 9 antibiotics with the methicillin sensitive S. aureus (MSSA) isolates.
Exfoliative toxin A (ETA) was more prevalent than B (ETB) with virulent determinants being additionally detected in multiple
drug-resistant isolates. 16S–23S ITS PCR-RFLP combined with sequencing of the primary product was successful in generating
molecular fingerprints of S. aureus and could be used for preliminary typing. This is the first study to demonstrate the incidence
of virulent genes, ACME, and genetic diversity of S. aureus isolates in Lebanon. The data presented here epitomize a starting point
defining the major genetic populations of both MRSA and MSSA in Lebanon and provide a basis for clinical epidemiological
studies.
1. Introduction
Staphylococcus aureus are extremely versatile pathogenic
bacteria that cause a wide range of syndromes, ranging
from minor skin and soft tissue infections to life-threatening
pneumonia and toxinoses [1]. The ability of S. aureus to
cause diseases is multifactorial, a combination of many
virulent factors including toxins, secreted exoproteins, and
cell surface-associated adhesins [2]. The diﬀerent virulent
factors expressed are controlled by a definite locus named
the accessory gene regulator (agr) and the staphylococcal
accessory regulator (sar) [3]. The exoproteins or exotoxins
include haemolysins, diﬀerent enzymes, and a family of
related pyrogenic toxins [4]. These pyrogenic toxins include
staphylococcal enterotoxin (SE) A-E and G-U subtypes,
toxic shock syndrome toxin-1 (TSST-1), and exfoliative
toxins (ET) A and B [3]. On the other hand, DNA
sequence analysis of the USA 300 clone identified a genetic
region and designated the arginine catabolic mobile element
(ACME). It was acquired horizontally from S. epidermidis
or other coagulase-negative staphylococci [4] and inhibited
polymorphonuclear cell production. ACME-encoded arcA
gene encodes for an arginine deiminase pathway and an
oligopeptide permease system enhancing colonization, vir-
ulence fitness of the strain, and is associated with invasive
diseases (necrotizing pneumonia) [5].
S. aureus resistance against a wide variety of antimicro-
bials is another important factor and is increasing world-
wide, including even resistance to vancomycin, the drug
of choice for staphylococcal infections [6]. Strains resistant
to penicillin, however, secrete β-lactamase (through blaZ
gene) that hydrolyses the β-lactam ring of the antibiotic [7].
Resistance to methicillin is encoded by the staphylococcal
cassette chromosome mec (SCCmec) element, composed of
the mec gene complex, and the ccr (cassette chromosome
recombinase) gene complex, encoding for the recombinase
gene [8]. SCCmec elements have been classified into eight
major types (I–VIII), some of which are diﬀerentiated
further into subtypes. SCCmec types I, II, and III, and types
IV and V have been associated with hospital-acquired (HA)
and community-acquiredmethicillin resistant S. aureus (CA-
MRSA), respectively.
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Typing is crucial in understanding the epidemiology of
pathogens and, hence, the development of public health
interventions. Ribotyping is a DNA-based typing method
based on the sequencing of the gene coding for rRNAs in
bacteria. Genes encoding for rRNA are arranged in an operon
in the following order 5′-16S-23S-5S-3′ and is separated
by two spacer regions known as the intergenic transcribed
spacer (ITS) [9]. The most commonly used components in
ribotyping are 16S rRNA gene and the 16S–23S ITS. The ITS
has proved to be more variable than the adjacent 16S and 23S
ribosomal genes and may allow eﬃcient identification at the
species level due to its variability within a genus [10]. This
variability is due partly to diﬀerences in the number and type
of tRNA sequences found within the spacer [11]. The use of
sequence polymorphisms and length variations found in the
ITS region as a tool for diﬀerentiation between closely related
organisms is increasing because it can overcome limitations
of the resolution of 16S rRNA-based phylogenies [12].
This study aims at characterizing 130 S. aureus clinical
isolates involved in human diseases based on the determina-
tion of antimicrobial resistance profiles, studying the preva-
lence of exfoliative toxins A (eta) and B (etb), enterotoxins
(SE) A-E and G-U, ACME, and TSST-1 and through
typing the isolates based on the size of the 16S–23S DNA
spacer region and on the patterns obtained by restriction
digestion of the amplified spacer region.
2. Materials and Methods
2.1. Clinical Isolates. 130 S. aureus clinical isolates from the
American University of Beirut Medical Center (AUB-MC)
were used in this study. The isolates were recovered from dif-
ferent sites of infection, age groups, and years. These isolates
were identified by diﬀerent methods including the API and
Biolog identification systems and the coagulase test.
2.2. Reference Strains. The following S. aureus reference
strains were used as positive controls: TC-142 (eta positive),
TC-7 (etb positive), and ATCC (BAA-1556D-5) (ACME pos-
itive); these strains were thankfully donated by Dr. Michele
Bes from the institute of Microbiology, Lyon-France and by
Dr. Binh An Diep from the university of California, San
Francisco. Reference strains also included the ATCC23235
(sed positive), ATCC27664 (see positive), NCTC 6571 (seg
and sei positive), NCTC11963 (tsst positive), ATCC13565
(sea positive), ATCC14458 (seb positive), ATCC19095 (sec
positive), and NCTC10652 (sej positive).
2.3.Bacterial Storage and Culture Conditions.All clinical isola-
tes were stored in CryoBank tubes (Copan, USA) at both
−20◦C and −80◦C.
2.4. Antimicrobial Susceptibility Testing (E-Test). The antimi-
crobial resistance of the clinical strains to diﬀerent antibac-
terial agents was determined by the standard E-test method
that comprises a predefined antibiotic gradient strips. Strips
were used according to the manufacturer instructions (AB
BIODISK, Sweden) to determine the minimum inhibitory
concentration (MIC) in μg/mL. Bacterial suspensions were
prepared by selecting colonies from overnight cultures on
mannitol salt agar plates. The colonies were suspended to
sterile tubes containing 5mL of saline solution (0.85% NaCl)
to get a suspension with a turbidity similar to the 0.5
McFarland standard. Mueller-Hinton agar plates (Oxoid)
were inoculated with the S. aureus clinical isolates, and 18
diﬀerent antibiotics were used including azithromycin (AZ),
ciprofloxacin (CI), clarithromycin (CH), clindamycin (CM),
chloramphenicol (CL), erythromycin (EM), gentamicin
(GM), levofloxacin (LE), nitrofurantoin (NI), norfloxacin
(NX), ofloxacin (OF), oxacillin (OX), rifampicin (RI),
teicoplanin (TP), tetracycline (TC), trimethoprim (TR),
trimethoprim/sulfamethoxazol (TS), and vancomycin (VA).
Plates were then incubated for 24 h at 37◦C. Following
incubation, MIC values that correspond to the edge of the
inhibition ellipse intersecting the side of the strips were deter-
mined. Resistance or susceptibility profiles were established
according to the Clinical and Laboratory Standards Institute
[13].
2.5. DNA Isolation and Extraction. Bacterial colonies were
cultured on TSA plates prior to extraction. Genomic DNA
was extracted using QIAamp DNA Mini kit (QIAGEN Inc,
Germany) following the manufacturer’s instructions.
2.6. PCR Amplification. All PCR assays were performed on
PerkinElmer GeneAmp 9700 (PerkinElmer, Wellesly, Mas-
sachusetts).
2.7. PCR for the Detection of eta and etb Encoding Gene.
Amplification was performed using the following protocol:
An aliquot of 5 μL of DNA (10 ng/μL) was added to 45 μL
of reaction mixture containing final concentrations of 1X
AmpliTaq buﬀer, 1.5mM MgCl2, 2.5U of AmpliTaq Gold
polymerase (Applied Biosystems, Roche), 200 μMeach deox-
ynucleoside triphosphate of either 1 μM of each of etaF
(5′-CTAGTGCATTTGTTATTCAA-3′) and etaR primers
(5′-TGCATTGACACCATAGTACT-3′) or 1 μM etbF (5′-
ACGGCTATATACATTCAATT-3′) and etbR primers (5′-
TCCATCGATAATATACCTAA-3′) [14, 15]. The amplifica-
tion was performed with an initial denaturation step for
10min at 95◦C followed by 33 cycles of 94◦C for 2min, 55◦C
for 1min, 72◦C for 1min, and a final extension at 72◦C
for 7min. PCR products were separated by electrophoresis
of 10 μL of reaction product in a 2% agarose gel stained
by 0.5 μg/mL ethidium bromide, and visualized using a UV
Bioimaging system (GeneSnap system from Syngene).
All PCR assay runs incorporated a negative (one reagent
control without template DNA) and a positive control (refe-
rence strain used for the gene amplified). Product size was
determined by comparison with a 100 bp molecular weight
marker (Fermentas, Vilnius, Lithuania).
2.8. PCR for the Detection of ACME. Amplification was per-
formed using the following protocol: An aliquot of 2 μL
of DNA was added to 20 μL of reaction mixture contain-
ing final concentrations of 1X AmpliTaq buﬀer, 2.5mM
MgCl2, 0.1U of AmpliTaq Gold polymerase (all from App-
lied Biosystems, Roche), 0.2mM each deoxynucleoside
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triphosphate, the junction between ACME and orfX was
amplified using 0.4 μM of the orfX-specific PCR primer
Xsau325 (5′-GGATCAAACGGCCTGCACA-3′), and 0.4 μM
AcmeR primer (5′-CCTCCTTCACTTAGCACTG-3′) [16].
The amplification was performed with an initial denatu-
ration step for 12min at 95◦C followed by 30 cycles of
94◦C for 30 sec, 61◦C for 30 sec, 72◦C for 1min, and a final
extension at 72◦C for 10min. PCR products were separated
by electrophoresis of 10 μL of reaction product in a 1.5%
agarose gel stained by 0.5 μg/mL ethidium bromide, and
visualized using a UV Bioimaging system (GeneSnap system
from Syngene).
2.9. Detection of Enterotoxins and tst Encoding Genes. Mul-
tiplex PCR assays were used to detect nine staphylococcal
enterotoxin (SE) genes sea, seb, sec, sed, see, seg, seh, sei,
sej, and the tst gene [17]. Two reaction mixtures were used,
primers for sed, see, seg, sei, and tsst were combined in
reaction mixture 1, and primers for sea, seb-sec, sec, she,
and sej were combined in reaction mixture 2. Amplification
was performed using 5 μL of DNA (10 ng/μL) added to
45 μL of reaction mixture containing final concentrations
of 1X AmpliTaq buﬀer, 4mM MgCl2, 2U of AmpliTaq
gold polymerase (Applied Biosystems, Roche), 400 μM each
deoxynucleoside triphosphate, 300 nM of each exotoxin
primer set. The amplification was performed with an initial
denaturation step for 10min at 95◦C followed by 15 cycles
of 95◦C for 1min, 68◦C for 45 s, 72◦C for 1min, 20 cycles
of 95◦C for 1min, 64◦C for 45 s, 72◦C for 1min, and a final
extension at 72◦C for 10min. PCR products were separated
by electrophoresis of 10 μL of reaction product in a 2.5%
agarose gel stained by 0.5 μg/mL ethidium bromide, at 100V
for 100min, and visualized using a UV Bioimaging system
(DigiDoc-IT system, version 2.2.0, 2003).
2.10. 16S–23S ITS rRNA Gene PCR Amplification. The
16S–23S ITS region was amplified using the following
protocol: an aliquot of 2 μL of DNA was added to 20 μL
of reaction mixture containing final concentrations of 1X
AmpliTaq buﬀer, 2.5mMMgCl2, 0.1U of AmpliTaq gold
polymerase (Applied Biosystems, Roche), 0.2mM each
deoxynucleoside triphosphate, 0.4 μM staph ITS-F primer
(5′-AGAGTTTGATCCTGGCTCAG-3′), 0.4 μM staph ITS-
R primer (5′-CAAGGCATCCACCGT-3′) [18]. The amplifi-
cation was performed with an initial denaturation step for
12min at 95◦C followed by 30 cycles of 94◦C for 30 sec, 42◦C
for 30 sec, 72◦C for 1min, and a final extension at 72◦C
for 10min. PCR products were separated by electrophoresis
of 10 μL of reaction product in a 1.5% agarose gel stained
with 0.5 μg/mL ethidium bromide, and visualized using a UV
Bioimaging system (GeneSnap system from Syngene).
2.11. 16S–23S ITS Restriction Digestion. The amplified 16S–
23S ITS rRNA gene fragments were digested with 10U TaqI
(MBI Fermentas) restriction enzyme. 1 μL of the enzyme
was added to 12 μL of the ITS PCR products, 16 μL water,
along with 2 μL 10x TaqI buﬀer for 3 h at 65◦C (Fermentas)
[18]. Products were resolved on a 2% agarose gels in 1x tris-
borate-EDTA buﬀer and were subsequently visualized by UV
illumination after ethidium bromide staining.
2.12. 16S–23S ITS Gel Extraction. Gel extraction of the 16S–
23S DNA spacer region primary product (1800 bp) was
performed using QIAquick Gel Extraction kit (QIAGEN Inc,
Germany) following the manufacturer’s instructions.
2.13. 16S–23S ITS Sequence Analysis. A 500 bp of the purified
DNA was subjected to direct sequencing using the Big
Dye Terminator Kit (ABI 3130xI Genetic Analyzer, Applied
Biosystems). Sequencing was performed in separate tubes,
and each reaction (10 μL) consisted of 5 μL of purified
DNA and 4 μL of Terminator Ready Reaction mix and
was amplified using 2 pmol of the staph ITS-F (5′-AGA
GTT TGA TCC TGG CTC AG-3′) and staph ITS-R (5′-
CAAGGCATCCACCGT-3′) primers in separate reactions
[18]. Sequence homology and identity comparison to other
sequences was performed with the NCBI-BLAST sequence
search. Phylogenetic tree was constructed by the neighbor–
joining method using the CLC Main Workbench version.
3. Results
3.1. Exfoliative Toxin-Encoding Genes (eta and etb) and
ACME. The exfoliative toxin genes were randomly dis-
tributed between the 93MRSA and 37MSSA. The prevalence
of eta within both groups was 11% while it was 3% for etb in
MRSA and 9% in MSSA. ACME was detected in one MSSA
isolate (Table 1). The eta gene (n = 14; 10.8%) was more
prevalent than etb (n = 6; 4.61%), and only three (2%) of the
tested isolates harbored both genes. The sizes of amplicons
obtained for the exotoxin genes were 119 and 200 bp for
eta and etb genes, respectively, and 333 bp for the ACME,
being same as those obtained for the reference strains TC-
7 (for eta), TC-142 (for etb), and BAA-1556D-5 (for ACME).
Majority of the isolates, which were previously typed by
Tokajian et al. [19] carrying the eta gene, belonged to spa
CC044 (21%) and spa CC008 (21%) while the etb-positive
isolates were detected mainly in CCe spa-clonal complex
(33%) and the ACME-positive isolate was of spa CCd type
(Table 1).
3.2. Prevalence of Enterotoxins. Isolates were also tested for
the presence of nine enterotoxin genes in addition to the
TSST-1 gene. The percentage of isolates harboring each of the
enterotoxins is shown in Table 2. The nine enterotoxin genes
were randomly distributed among the MSSA and the MRSA
with the number of toxins detected/isolate ranging between 0
and 4 (Table 3). The gene for the tsst was detected in 7 isolates
with all being MSSA. Most of the isolates having more than
one enterotoxin (4 genes) were resistant on average to only
one antibiotic.
3.3. Resistance to Antibiotics. The percentage of resistant
isolates to each of the tested antibiotics is shown in Figure 1.
All isolates tested showed no resistance to vancomycin, 2% to
chloramphenicol and only one showed resistance to nitrofu-
rantoin and teicoplanin. The highest percentage of resistance
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Table 1: Characteristics of MRSA and MSSA isolates harboring the ACME, eta and etb genes (spa and mec typing retrieved from Tokajian et
al. [19]).
No. of isolates MRSA/MSSA (SCC mec subtype)a spa typeb Toxins (ETA and ETB)c
3 MRSA (IVc) t044 ETA
1 MRSA (IVc) t032 ETA, ETB
1 MRSA (III) t021 ETA
1 MRSA (IVc) t037 ETA
1 MRSA (IVc) t008 ETA
1 MSSA t937 ACME
1 MSSA t1439 ETA
1 MSSA t2179 ETA
1 MRSA (IVc) t304 ETA
1 MRSA (II) t002 ETA
1 MSSA t729 ETB
1 MRSA (IVc) t3468 ETB
1 MRSA (IVc) t537 ETA, ETB
1 MSSA t159 ETA, ETB
1 MSSA t209 ETA
1 MSSA t1515 ETB
a
MRSA: methicilin Resistant Staphylococcus aureus, MSSA: Methicilin Sensitive Staphylococcus aureus, SCCmec: staphylococcal cassette mec.
bspa: Staphylococcus aureus Protein A.
cETA: exfoliative toxin A; ETB: exfoliative toxin B.
Table 2: Percentage of isolates harboring the diﬀerent exotoxin
genes.
Enterotoxin genesa
% of isolates harboring enterotoxins
(number)
Sea 25 (n = 33)
Seb 8 (n = 11)
Sec 5 (n = 6)
Sed 11 (n = 14)
See 0 (n = 0)
Seg 25 (n = 32)
She 7 (n = 9)
Sei 60 (n = 77)
Sej 1.5 (n = 2)
Tsst 5 (n = 7)
a
Sea-j: staphylococcal Enterotoxin a-j, Tsst: toxic shock Syndrome Toxin.
was to oxacillin (32%; n = 41) and tetracycline (42%;
n = 54). Resistance to other antibiotics was intermediate,
ranging between 7% to rifampicin and 25% (n = 33) to
azithromycin. Multiple drug resistance was detected in both
MSSA and MRSA with the maximum number being to
14 drugs (Table 3). Resistance to 10–14 drugs was mainly
detected in MRSA mec subtypes II and III except for one
isolate being resistant to 13 and having mec subtype IV.
3.4. 16S–23S ITS rRNA Gene PCR Amplification. The 16S-
ITS rRNA gene was amplified in 15 S. aureus isolates
representing the major spa types. PCR-mediated amplifica-
tion of this region revealed the presence of two ribotypes.
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Figure 1: The percentage of resistant isolates to each of the tested
antibiotics. The eighteen antimicrobial agents used were azithro-
mycin (AZ), ciprofloxacin (CI), clarithromycin (CH), clindamycin
(CM), chloramphenicol (CL), erythromycin (EM), gentamicin (GM),
levofloxacin (LE), nitrofurantoin (NI), norfloxacin (NX), ofloxacin
(OF), oxacillin (OX), rifampicin (RI), teicoplanin (TP), tetracycline
(TC), trimethoprim (TR), trimethoprim/sulfamethoxazol (TS),
and vancomycin (VA).
Almost 87% of the isolates belonged to ribotype I with two
amplification products size of which were 1500 and 1800 bp.
Ribotype II represented 13% of the isolates and gave one
band with a size of 1800 bp (Figure 2). All the isolates gave an
intense band at 1800 bp, which was designated as the primary
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Table 3: Characterization of S. aureus isolates through the determination of antibiotic resistance profiles and prevalence of virulence factors.
MRSA (93 Isolates)a Number of drugs eta genec etb genec Enterotoxins and TSST-1d
n = 59 0–2 7% 3% 0–5%
n = 23 3–9 26% 13% 0–13%
n = 11 10–14 18% 0 0–27%
MSSA (37 Isolates)b Number of drugs eta gene etb gene Enterotoxins and TSST-1
n = 27 0–2 11% 0% 0–15%
n = 12 3–9 8% 8% 0–33%
a
MRSA: methicilin resistant Staphylococcus aureus.
b MSSA: methicilin sensitive Staphylococcus aureus.
ceta: exfoliative toxin A), etb: exfoliative toxin B.
d TSST-1: toxic shock syndrome toxin-1.
Table 4: Restriction patterns of the 16S–23S ITSa-amplified products.
Groups Restriction patterns Isolates no. Sizes of the amplification products
I
1 n = 10 (S1, 3,12, 34, 38, 40, 111, 113, 121, and 130) 150, 250, 325, 350, 450, 650, 725, 900
2 n = 1 (S19) 150, 350, 650,750, 900
3 n = 1 (S75) 150, 350, 450, 675, 700, 900
4 n = 1 (S88) 170,250, 325, 350, 750, 900
II 5 n = 2 (S78, and 89) 150,250,325,350, 900
a
ITS: internal transcribed spacer.
1 2 3 4 5 6 7 8 9
2500 bp
2000 bp
1500 bp
1000 bp
500 bp
Figure 2: Gel electrophoresis showing 16S–23S DNA spacer region
(ITS) amplification products. Lane 1: 500 bp DNA ladder; lanes 2,
and 3: negative control (water); lanes 4, 5, 7, 8, and 9: 16S–23S (ITS)
positive isolates that belong to ribotype I (1500 bp and 1800 bp);
lane 6: 16S–23S (ITS) positive isolate that belong to ribotype II
(1800 bp).
product, and most had an additional band, which appeared
weaker and was designated as secondary product.
16S–23S ITS-amplified products were digested using
TaqI restriction enzyme (Table 4 and Figure 3). Elec-
trophoresis and fragment size analysis of restriction products
revealed the presence of five banding patterns [four patterns
in Ribotype I (lanes 3, 5, 7, and 13) and only one in Ribotype
II (lanes 14 and 16)], but the diﬀerence only between
Ribotype I and II was significant enough totaling to three
bands (Figure 3).
3.5. Phylogenetic Analysis. To evaluate the phylogenetic rela-
tionships between the 15 S. aureus representative isolates,
we extracted and partially sequenced the 16S–23S ITS rDNA
primary product (1800 bp) that was detected in all. Twomain
clusters were detected and designated as A and B. The first
contained S78 (MSSA spa t1149) and S89 (MSSA spa t937)
isolates, and the second contained S1 (MRSA-IV spa t044),
S3 (MRSA-II spa t002), S12 (MSSA spa t008), S19 (MRSA-
IV spa t068), S34 (MRSA-V spa t267), S38 (MRSA-III spa
t044), S40 (MRSA-IV spa t537), S75 (MSSA spa t021), S88
(MSSA t055), S111 (MRSA-IV spa t4098), S113 (MRSA-
IV spa t279), S121 (MRSA-IV spa t660), and S130 (MRSA-
IV spa t044) isolates. In cluster A both strains were closely
related. Sequencing of the primary product revealed that
Ribotype I representatives belonged to cluster A, while all
other isolates representing Ribotype II were in cluster B.
Additionally strains showing similar restriction patterns were
clustered together (S1, S34, S38, and S40 all had the same
restriction pattern the same applies for S78 and S89).
4. Discussion
S. aureus is one of the most common causes of CA- and HA-
localized and -systemic infections. Nearly all isolates of S.
aureus produce enzymes and a range of more than 30 diﬀer-
ent extracellular proteins, most of which play a direct role in
pathogenesis [20]. This study aimed at defining the preva-
lence of virulent determinants (exfoliative toxins, entero-
toxins, TSST-1, and ACME), drug resistance and typing
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Figure 3: Restriction digestion patterns of the 16S–23S internal transcribed spacer (ITS) amplicons with TaqI. Lane1: 100 bp ladder; lane 2:
negative control (water); lanes 3, 5, 7, 10, 11, 12, 17, 18, 19, and 20: ITS restriction products for pattern I; lane 9: ITS restriction products for
pattern II; lane 13: ITS restriction products for pattern III; lane 15: ITS restriction products for pattern IV; lanes 14 and 16: ITS restriction
products for pattern V.
of a diverse set of 130 S. aureus clinical isolates. The eta
gene (11%; n = 14) was more frequently detected than
the etb gene (5%; n = 6), and only 2.3% (n = 3) of all
isolates tested harbored both genes. Landhani et al. [20]
in the United Kingdom and Ireland, showed that 32% of
S. aureus isolates produced ETA and only 12% produced
ETB. The higher prevalence of the eta gene in staphylococci
could be explained by its greater immunogenicity [21].
There are reported geographic variations in the prevalence
of diﬀerent ET isoforms. The majority of previous reports
confirmed that ETA was the predominant ET isoform in
Europe, North America, and Africa which was similar to
our findings, whereas ETB-producing isolates were shown
to be more frequent in Japan [20–23]. ACME contributed
to the success in disseminating the USA300 isolate through
enhancing virulence and colonization of humans. In this
study, ACME was detected in only one MSSA isolate that
was recovered from a skin infection. Goering et al. [16]
however, also revealed that only 2 out of 22 USA300 MSSA
isolates from California and Nevada were ACME positive.
To date, ACME has been reported predominantly among
USA300 isolates harboring specific SCCmec types (IVa and
II) and MLST clonal complexes (CCs) (CC8 and CC5)
genetic background, and it has been detected also in England
among S. aureus isolates with SCCmec type IVa [16, 24].
The three virulent determinants (eta, etb, and ACME) in this
study were variably distributed among 16 diﬀerent spa types
belonging to 12 diﬀerent spa CCs, possibly because they are
located on prophage, plasmid, and a pathogenicity island,
which are mobile vectors of horizontal transfer [24].
Moreover, the most prevalent enterotoxin gene among
the tested isolates in this study was sei (59%), which agreed
with the findings of Becker et al. [25] in Germany (55%)
while it was the sea in Jordan (65%) [26]. Percentage of
isolates positive for seb was 8, which was again in harmony
with the results obtained by Becker et al. [25]. In contrast,
25% of the isolates harbored the seg gene compared to only
1.4% in Japan [27]. The gene coding for TSST-1, however,
was detected only in 7% of the isolates in this study, which
matched with the results of Srinivasan et al. [28] in the
United States but was lower than the percentage reported by
Becker et al. [25] (20%). It’s interesting to note that none
of the isolates undertaken in this study had the see gene,
which was the case with clinical isolates studied in Jordan
[26]. On the other hand, isolates harboring the enterotoxin
genes were randomly distributed among males and females,
age categories, site and date of infection, and type (MSSA
versus MRSA). It was notable that tst-positive isolates were
all MSSA, being recovered from abscesses, pus, sputum,
or blood. Finally, isolates harboring toxin genes were not
multiple drug resistant, and the opposite was also true.
Multidrug resistance is very common in S. aureus, which
is now considered as a leading cause of nosocomial infections
[27]. The widespread S. aureus isolates that are resistant
to many antimicrobial agents such as the semisynthetic
penicillins (methicillin, oxacillin, and nafcillin), macrolides,
tetracyclines, and aminoglycosides made the treatment of
staphylococcal infections a global challenge [28]. In this
study, resistance to tetracycline was the highest (48%) with
similar result being previously obtained by Hamze et al.
[29] with samples collected from north Lebanon (44%).
Percentage of resistant strains, however, was higher in
Australia (80%) [30], while lower in the United States (5%)
[31]. Almost 32% of the isolates undertaken in this study
were oxacillin resistant which was significantly lower than
the percentage detected in Belgium (almost 99%) by Maskell
et al. [32]. Percentage of resistance to azithromycin (25%),
trimethoprim (24%), and erythromycin (24%) was almost
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the same andwas in harmony with resistance to azithromycin
in the UK (23%) and the United States (26%) [31, 32]; it
was lower for azithromycin (12%) in Japan [33] and higher
to trimethoprim in the UK (69%) [34] and Australia (82%)
[30]. This study also revealed an increase in the percentage of
strains resistant to erythromycin (24%) compared to results
obtained by Baddour et al. [35] where the percentage of
resistant strains were much lower being only 7%. Resistance
reported for erythromycin was higher in the UK [34] and
Australia [30] being 90% and 89%, respectively, while only
12% in Japan [33]. It’s noteworthy that almost 15% of
the isolates were resistant to trimethoprim/sulfamethoxazol,
which agreed with results obtained by Baddour et al. [35].
A significant increase was also detected in this study with
the percentage of isolates resistant to clindamycin (22%)
and gentamicin (9%) compared to what was reported
previously [29] with only 4% of the strains being resistant to
clindamycin and 3% to gentamicin. The percentage of strains
resistant to teicoplanin, nitrofurantoin, chloramphenicol,
and vancomycin detected in this study was either very low
or absent. Similar results were also previously reported for
both teicoplanin and vancomycin [34–36] while it was higher
to chloramphenicol [34, 35]. Multiple drug resistance was
detected in both MSSA and MRSA with the maximum
number being to 14 drugs. Resistance to 10–14 drugs was
mainly detected in MRSA mec subtypes II and III except for
one isolate being resistant to 13 and having mec subtype IV.
These findings confirm along with themec subtyping that the
majority of themultiple drug-resistant isolates probably were
hospital acquired.
The 16S–23S internal transcribed spacer (ITS) PCR
amplification can be used for typing S. aureus strains.
This region is known to be extremely variable between
species, strains, and even among diﬀerent operons within the
same cell and has been widely used to study evolutionary
relationships among closely related microorganisms [37, 38].
Amplification of the 16S–23SDNA spacer region revealed the
presence of two ribotypes. Ribotype I gave two amplification
products with a size of 1500 and 1800 bp, which was
consistent with the findings of Sudagidan et al. [18], while
ribotype II gave one intense band at position 1800 bp.
Ribotype I was the most frequent accounting for 87% of
the isolates, whereas ribotype II represented only 13%. Most
of the isolates gave additional weaker band, and the source
of this secondary product might be the presence of more
than one rRNA operon in those isolates with the upper band
(1800 bp) containing one or two tRNAs and the lower band
(1500 bp) none or only one tRNA-encoding gene [39, 40].
Couto et al. [39] characterized the spacer sequences of S.
aureus strains and identified 9 rRNA operons, and reported
that 3 of these spacers contained the tRNAIle gene and 2
contained both the tRNAIle and the tRNAAla genes, while
the remaining 4 16S–23S spacers have no tRNA gene. It is
noteworthy that the observed ITS size variability alone was
not enough to subtype S. aureus isolates at the strain level,
and consequently the amplified 16S–23S DNA spacer region
was subjected to restriction digestion using TaqI restriction
enzyme. Previously, ITS RFLP using TaqI has been employed
for the identification of bacteria of diverse origin including
lactobacilli, thermophilic bacilli [40], and alkalophilic bacilli
[41] and was also used by Sudagidan et al. [18] for subtyping
16 staphylococcal species in Turkey. Our results revealed 5
distinct RFLP haplotypes, with those belonging to ribotype
I having 4 restriction patterns that matched with the results
of Sudagidan et al. [18], while isolates belonging to diﬀerent
ribotypes generated diﬀerent restriction patterns. This study
didn’t reveal any correlation between ITS ribotyping and
prevalence of the virulent determinants.
Combining 16S–23S ITS PCR-RFLP with partial
sequencing of the primary product and the construction
of a phylogenetic tree revealed the presence of 2 clusters A
and B. Isolates belonging to each cluster harbored the same
ITS amplicon sizes and similar restriction patterns. These
findings matched with the results of Osorio et al. [42], who
reported that the intraspecies evolutionary divergence is due
to polymorphisms clustered within the ITS variable region
where a number of insertion and deletion events occur. The
ITS-based identification method can be used to generate
molecular fingerprints of S. aureus for characterization of
isolates and could have useful applications for evolutionary
studies. The major drawback, however, is the absence of
suﬃcient information about rRNA copy number and size,
the number of tRNA encoding genes and ITS sequence and
size in S. aureus isolates.
5. Conclusion
To the extent of our knowledge, this is the first study that
demonstrates the prevalence of virulent determinants and
describes the use of 16S–23S ITS PCR-RFLP and its partial
sequencing for the subtyping S. aureus isolates in Lebanon.
The results show that the virulence gene content of S. aureus
isolated from Lebanon varies widely. The use of eﬃcient and
accurate epidemiological typing methods is a prerequisite for
monitoring and for limiting the occurrence and spread of
epidemic clones within and between hospitals.
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